M&T Bank’s Intellia Therapeutics NTLA Stock Holding History

M&T Bank’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-7,405	Closed	-$403K	–	1664
2020 Q4	$403K	Sell	7,405 -11,727	-61%	-$426K	﹤0.01%	1172
2020 Q3	$380K	Buy	19,132 +16	+0.1%	+$334	﹤0.01%	1110
2020 Q2	$402K	Buy	19,116 +412	+2%	+$7K	﹤0.01%	1041
2020 Q1	$229K	Hold	18,704	–	–	﹤0.01%	1272
2019 Q4	$274K	Hold	18,704	–	–	﹤0.01%	1132
2019 Q3	$250K	Hold	18,704	–	–	﹤0.01%	1308
2019 Q2	$306K	Hold	18,704	–	–	﹤0.01%	1217
2019 Q1	$319K	Buy	+18,704	New	+$279K	﹤0.01%	1176
2018 Q4	–	Sell	-7,914	Closed	-$226K	–	1522
2018 Q3	$226K	Hold	7,914	–	–	﹤0.01%	1375
2018 Q2	$216K	Buy	+7,914	New	+$192K	﹤0.01%	1392
2018 Q1	–	Sell	-11,516	Closed	-$221K	–	1617
2017 Q4	$221K	Hold	11,516	–	–	﹤0.01%	1388
2017 Q3	$286K	Hold	11,516	–	–	﹤0.01%	1257
2017 Q2	$184K	Hold	11,516	–	–	﹤0.01%	1421
2017 Q1	$162K	Buy	+11,516	New	+$155K	﹤0.01%	1481

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

M&T Bank's NTLA Position: Q1 2021 in Review

M&T Bank sold out of Intellia Therapeutics (NTLA) in Q1 2021, closing a stake of 7,405 shares — an estimated $403K sold.

M&T Bank first reported a position in NTLA in Q1 2017 and held it in 14 quarters. The position peaked at $403K in Q4 2020. 260 funds tracked by Wall St. Rank hold NTLA as of Q1 2021.

M&T Bank reported no remaining Intellia Therapeutics position as of Q1 2021 after selling out during the quarter.
M&T Bank sold 7,405 Intellia Therapeutics shares in Q1 2021, an estimated $403K.
M&T Bank first reported a position in Intellia Therapeutics in Q1 2017 and held it in 14 quarters.
M&T Bank's Intellia Therapeutics position peaked at $403K in Q4 2020.
260 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2021.

Based on M&T Bank's 13F filing for Q1 2021, filed 6 May 2021.